OPSYNVI® (macitentan and tadalafil)
- Disease state information & resources
- Guidelines
- Pivotal clinical trial publications
- Risk evaluation and mitigation strategy (REMS)
- Search medical information
- U.S. FDA approves OPSYNVI® (macitentan and tadalafil) as the first and only once-daily single-tablet combination therapy for patients with pulmonary arterial hypertension (PAH)